SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Atossa Therapeutics, Inc. (ATOS) News

Follow Atossa Therapeutics, Inc. (ATOS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol ATOS Asset equity Sector Markets 90 days 4 Last 1.795 Updated Sep 29, 2026, 12:03 PM UTC Open live news feed Open ATOS chart & news
L Atossa to Issue CVRs Giving Shareholders Claim on 25% of First Voucher Proceeds, Capped at $50M Atossa will issue one contingent value right per share giving holders a contractual claim to 25% of net proceeds from the company's first qualifying rare pediatric disease priority review voucher, capped at $50 million.K REGULATION | Sep 29, 2026, 12:03 PM UTC L Atossa Therapeutics, Inc. (ATOS) Plans CVR Paying Up To $50M From Potential PRV Atossa approved issuing one CVR per share, entitling holders to 25% of net proceeds from monetizing its first qualifying FDA priority review voucher, capped at $50M. No product is approved and no voucher has been awarded REGULATION | Sep 29, 2026, 12:01 PM UTC L Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher Shareholders would receive one CVR for each ATOS share held as of the record date or issued thereafterCVRs would entitle holders to 25% of net proceeds from monetization of Atossa's first qualifying priority review vouch NEWS | Sep 29, 2026, 12:00 PM UTC L ATOS - Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging ATOS - Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging NEWS | Sep 24, 2026, 12:01 PM UTC L ATOS ATOS - Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti- Cancer Activity in ATOS ATOS - Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti- Cancer Activity in ER- Positive Breast Cancer EQUITY | Jul 28, 2026, 12:31 PM UTC